Which Japanese drugmakers are leading in AI adoption?

Takeda Pharmaceutical and Chugai Pharmaceutical report the highest active usage rates, exceeding 60%, and have built company-wide AI platforms. Daiichi Sankyo, Shionogi, and Otsuka Holdings are also advancing drug discovery and supply-chain applications. Astellas Pharma and Eisai disclosed no individual projects in their filings to date.

What are drugmakers using AI for?

The primary focus is research and development—including drug discovery platforms, clinical development, and predicting new technologies. Secondary applications include manufacturing (predictive equipment maintenance), inventory optimization, and supply-chain forecasting. Sales support received minimal mention in Japanese filings, unlike foreign peers.

What is slowing broader AI adoption?

Personnel and organizational readiness are the main constraints. Otsuka launched an "Otsuka Digital Academy" in July 2025 to train leaders and raise employee literacy; Kyowa Kirin is doing the same, building digital project planners and bottom-up literacy education. Both companies are prioritizing human infrastructure before full rollout.

Back to articlesTop Companies' AI Moves

Top Companies' AI Moves

Japan's major pharmaceutical companies are embedding AI into core drug discovery and business operations, with adoption rates rising sharply—signaling that laggards risk competitive disadvantage.

Top Companies AI — Japan (2/2)1d ago6 min read

Key takeaway

Japan's major pharmaceutical firms—Takeda, Chugai, Daiichi Sankyo, Shionogi, and others—are now reporting substantial AI integration in financial filings, with adoption rates exceeding 60% among staff and AI recognized as essential to drug discovery and operational efficiency. Companies that lag in AI readiness risk losing research leadership and competitive standing, as the industry moves from pilot projects to company-wide implementation by 2030.

Summaries like this, in your inbox every morning.

3 Key Points

What happened
Japanese drugmakers including Takeda Pharmaceutical, Chugai Pharmaceutical, and others disclosed in their 2025–2026 financial filings that they are deploying AI across research, manufacturing, and supply chains. Takeda reported that 63% of employees actively use generative AI tools as of March 2025, up 16 percentage points in one year; Chugai said active users exceed 60%.
Why it matters
Pharmaceutical companies now view AI delays as a material business risk. Daiichi Sankyo explicitly warned that falling behind in AI innovation could erode research-and-development advantage and lower competitive strength. AI has shifted from an IT-department project to a core business strategy, affecting how companies develop drugs, predict inventory, and manage operations—meaning uneven adoption across firms may widen the performance gap by 2030.
What to watch
Mid-tier firms lag significantly—only a handful mentioned AI in their filings, and those that did offered little detail. Large companies like Takeda are embedding AI across the entire value chain (from target discovery to commercialization), while Chugai and others partner with external firms (Chugai with SoftBank on autonomous AI agents for clinical development) to secure competitive advantage in drug productivity.

FAQ

Which Japanese drugmakers are leading in AI adoption?: Takeda Pharmaceutical and Chugai Pharmaceutical report the highest active usage rates, exceeding 60%, and have built company-wide AI platforms. Daiichi Sankyo, Shionogi, and Otsuka Holdings are also advancing drug discovery and supply-chain applications. Astellas Pharma and Eisai disclosed no individual projects in their filings to date.
What are drugmakers using AI for?: The primary focus is research and development—including drug discovery platforms, clinical development, and predicting new technologies. Secondary applications include manufacturing (predictive equipment maintenance), inventory optimization, and supply-chain forecasting. Sales support received minimal mention in Japanese filings, unlike foreign peers.
What is slowing broader AI adoption?: Personnel and organizational readiness are the main constraints. Otsuka launched an "Otsuka Digital Academy" in July 2025 to train leaders and raise employee literacy; Kyowa Kirin is doing the same, building digital project planners and bottom-up literacy education. Both companies are prioritizing human infrastructure before full rollout.

Discussion

No comments yet. Be the first to share your thoughts!

Arista Networks' balance sheet revealed a buildup of AI chip orders and deferred revenue months before its stock surged 76%, showing how close readers of financial details could have spotted the boom.

Top Companies AI — US (2/2)8h ago

Thermo Fisher Scientific is showcasing AI-powered mass spectrometry tools and integrated laboratory solutions at BIO 2026, positioning itself as a single partner for drug development from discovery through manufacturing.

Top Companies AI — US (2/2)8h ago

Salesforce launches Help Agent, a prebuilt AI customer service tool that charges based on resolved issues rather than usage metrics, becoming available in July 2026.

Top Companies AI — US (2/2)8h ago

CFOs warn that AI success in finance requires heavy investment in employee training, not just technology—but most companies spend 93% on tech and only 7% on people.

Top Companies AI — US (2/2)8h ago

Life sciences executives gather to argue that AI agents need a trustworthy data foundation before deployment—not the other way around.

Top Companies AI — US (2/2)8h ago

Corning, a century-old glassmaker, has become a major AI infrastructure winner as hyperscalers lock in long-term fiber and optical equipment deals to power sprawling data centers.

Top Companies AI — US (2/2)8h ago

Stay ahead with AI news

Get curated AI news from 200+ sources delivered daily to your inbox. Free to use.

Get Started Free

Free · takes 30 seconds · unsubscribe anytime

5 minutes a day. The AI essentials.

200+ sources · Email / LINE / Slack

Get it free →

Japan's major pharmaceutical companies are embedding AI into core drug discovery and business operations, with adoption rates rising sharply—signaling that laggards risk competitive disadvantage.

Key takeaway

3 Key Points

FAQ

Discussion

Related Articles

Arista Networks' balance sheet revealed a buildup of AI chip orders and deferred revenue months before its stock surged 76%, showing how close readers of financial details could have spotted the boom.

Thermo Fisher Scientific is showcasing AI-powered mass spectrometry tools and integrated laboratory solutions at BIO 2026, positioning itself as a single partner for drug development from discovery through manufacturing.

Salesforce launches Help Agent, a prebuilt AI customer service tool that charges based on resolved issues rather than usage metrics, becoming available in July 2026.

CFOs warn that AI success in finance requires heavy investment in employee training, not just technology—but most companies spend 93% on tech and only 7% on people.

Life sciences executives gather to argue that AI agents need a trustworthy data foundation before deployment—not the other way around.

Corning, a century-old glassmaker, has become a major AI infrastructure winner as hyperscalers lock in long-term fiber and optical equipment deals to power sprawling data centers.

Stay ahead with AI news